New York, New York-- (Newsfile Corp. - March 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate ...

On this news, the price of TransMedics stock fell $3.74 per share, or 5.15%, to close at $68.81 on January 10, 2025. On January 13, 2025, TransMedics stock fell a further $4.76 per share, or 6.9%, to ...

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

Equities research analysts at William Blair raised their Q3 2025 earnings estimates for shares of TransMedics Group in a ...

TransMedics Group Inc (TMDX) reports a robust 50% year-over-year revenue growth, improved profitability, and strategic expansions despite facing operational challenges and market variability.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as a buy.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...